Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New Cancer Drugs Fund provides faster access to effective cancer treatments
NICE will now be able to make decisions on cancer drugs faster than ever before. For the first time NICE will issue draft guidance on new cancer drugs
NICE will now be able to make decisions on cancer drugs faster than ever before. For the first time NICE will issue draft guidance on new cancer drugs
DiCE is a privately-held startup, which focuses on the development of next-generation methods to small molecule drug discovery. The collaboration will see Sanofi pay an initial $50m to
A recent survey commissioned by the makers of Children’s Flonase Allergy Relief revealed that a majority of parents of young children with seasonal allergies tend to limit their
Repros is seeking the enclomiphene marketing authorization for Europe through a central filing which is valid in all European Union and European Economic Area countries, i.e. 31 countries
The procedure, involving a single injection of hRPC cells under the retina, was conducted at Massachusetts Eye and Ear in Boston, a teaching affiliate of Harvard Medical School
RPL554 is a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule, currently in development as a nebulised treatment for acute exacerbations in
The review has been started because an increased rate of serious adverse events including deaths, mostly due to infections, was seen in three clinical trials1 investigating the medicine
The trial is a double-blind, placebo-controlled, three arm, multicenter study enrolling approximately 350 patients with Lactose Intolerance symptoms. Patients will undergo a 30-day treatment process, followed by a
The Prescription Drug User Fee Act (PDUFA) action date for completion of FDA review of the eteplirsen is May 26, 2016. The FDA has granted eteplirsen Priority Review
This is the second orphan drug designation obtained by ProNAi for PNT2258 for the treatment of DLBCL, following a similar grant by the European Commission in August 2015.